Biopharmaceutical CMO & CRO Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global biopharmaceutical CMO (Contract Manufacturing Organization) & CRO (Contract Research Organization) market looks promising with opportunities in the pharmaceutical, biotechnological, and medical device industries. The global biopharmaceutical CMO & CRO market is expected to grow with a CAGR of 7%-9% from 2020 to 2025. The major drivers for this market are increasing demand for biologics, rising biopharmaceutical industry, and time and cost saving benefits offered to biopharmaceutical companies by contract services.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biopharmaceutical CMO & CRO market report, please download the report brochure.
In this market, biologics is the largest product type of biopharmaceutical CMO & CRO, whereas mammalian is the largest source. Growth in various segments of the biopharmaceutical CMO & CRO market are given below:
The study includes trends and forecast for the global biopharmaceutical CMO & CRO market by product, service, source, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
? Upstream
Lucintel forecasts that biologics will remain the largest product segment over the forecast period due to complex manufacturing steps, high specificity of biologics, and a higher success rate than other drug molecules.
Within this market, mammalian will remain the largest segment by source over the forecast period due to their capabilities of adding human-like post-translational modifications to complex protein therapeutics and new developments in this segment, leading to more productive and efficient manufacturing of biologics using mammalian cells.
North America will remain the largest region over the forecast period due to the presence of a large number of small and mid-size biopharmaceutical entities (SMEs) that are lacking the resources and budget to establish facilities with well-equipped resources in the region.
Features of the Global Biopharmaceutical CMO & CRO Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global biopharmaceutical CMO & CRO market by product (biologics (monoclonal antibodies (MAbs), recombinant proteins, vaccines, antisense, RNAi, & molecular therapy, and others) and biosimilars), service (contract manufacturing (process development (downstream and upstream), fill & finish operations, analytical & QC studies, and packaging) and contract research (oncology, inflammation & immunology, cardiology, neuroscience, and others)), source (mammalian and non-mammalian), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biopharmaceutical CMO & CRO market?
Q.5 What are the business risks and threats to the global biopharmaceutical CMO & CRO market?
Q.6 What are the emerging trends in this biopharmaceutical CMO & CRO market and the reasons behind them?
Q.7 What are some changing demands of customers in this biopharmaceutical CMO & CRO market?
Q.8 What are the new developments in this biopharmaceutical CMO & CRO market? Which companies are leading these developments?
Q.9 Who are the major players in this biopharmaceutical CMO & CRO market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biopharmaceutical CMO & CRO market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biopharmaceutical CMO & CRO market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars), Service (Contract Manufacturing (Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)), Source (Mammalian and Non-Mammalian)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global biopharmaceutical CMO (Contract Manufacturing Organization) & CRO (Contract Research Organization) market looks promising with opportunities in the pharmaceutical, biotechnological, and medical device industries. The global biopharmaceutical CMO & CRO market is expected to grow with a CAGR of 7%-9% from 2020 to 2025. The major drivers for this market are increasing demand for biologics, rising biopharmaceutical industry, and time and cost saving benefits offered to biopharmaceutical companies by contract services.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biopharmaceutical CMO & CRO market report, please download the report brochure.
In this market, biologics is the largest product type of biopharmaceutical CMO & CRO, whereas mammalian is the largest source. Growth in various segments of the biopharmaceutical CMO & CRO market are given below:
The study includes trends and forecast for the global biopharmaceutical CMO & CRO market by product, service, source, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
- Biologics
- Monoclonal Antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi (Ribonucleic Acid Interference), & Molecular Therapy
- Others
- Biosimilars
- Contract Manufacturing
- Process Development
? Upstream
- Fill & Finish Operations
- Analytical & QC (Quality Control) Studies
- Packaging
- Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
- Mammalian
- Non-Mammalian
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Spain
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- The Rest of the World
- Brazil
Lucintel forecasts that biologics will remain the largest product segment over the forecast period due to complex manufacturing steps, high specificity of biologics, and a higher success rate than other drug molecules.
Within this market, mammalian will remain the largest segment by source over the forecast period due to their capabilities of adding human-like post-translational modifications to complex protein therapeutics and new developments in this segment, leading to more productive and efficient manufacturing of biologics using mammalian cells.
North America will remain the largest region over the forecast period due to the presence of a large number of small and mid-size biopharmaceutical entities (SMEs) that are lacking the resources and budget to establish facilities with well-equipped resources in the region.
Features of the Global Biopharmaceutical CMO & CRO Market
- Market Size Estimates: Global biopharmaceutical CMO & CRO market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global biopharmaceutical CMO & CRO market size by various segments, such as product, service, and source in terms of value.
- Regional Analysis: Global biopharmaceutical CMO & CRO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product, service, source, and region for the global biopharmaceutical CMO & CRO market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biopharmaceutical CMO & CRO market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global biopharmaceutical CMO & CRO market by product (biologics (monoclonal antibodies (MAbs), recombinant proteins, vaccines, antisense, RNAi, & molecular therapy, and others) and biosimilars), service (contract manufacturing (process development (downstream and upstream), fill & finish operations, analytical & QC studies, and packaging) and contract research (oncology, inflammation & immunology, cardiology, neuroscience, and others)), source (mammalian and non-mammalian), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biopharmaceutical CMO & CRO market?
Q.5 What are the business risks and threats to the global biopharmaceutical CMO & CRO market?
Q.6 What are the emerging trends in this biopharmaceutical CMO & CRO market and the reasons behind them?
Q.7 What are some changing demands of customers in this biopharmaceutical CMO & CRO market?
Q.8 What are the new developments in this biopharmaceutical CMO & CRO market? Which companies are leading these developments?
Q.9 Who are the major players in this biopharmaceutical CMO & CRO market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biopharmaceutical CMO & CRO market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biopharmaceutical CMO & CRO market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars), Service (Contract Manufacturing (Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)), Source (Mammalian and Non-Mammalian)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biopharmaceutical CMO & CRO Market Trends and Forecast
3.3: Global Biopharmaceutical CMO & CRO Market by Product
3.3.1: Biologics
3.3.1.1: Monoclonal Antibodies (MAbs)
3.3.1.2: Recombinant Proteins
3.3.1.3: Vaccines
3.3.1.4: Antisense, RNAi, & Molecular Therapy
3.3.1.5: Others
3.3.2: Biosimilars
3.4: Global Biopharmaceutical CMO & CRO Market by Service
3.4.1: Contract Manufacturing
3.4.1.1: Process Development
3.4.1.1.1: Downstream
3.4.1.1.2: Upstream
3.4.1.2: Fill & Finish Operations
3.4.1.3: Analytical & QC Studies
3.4.1.4: Packaging
3.4.2: Contract Research
3.4.2.1: Oncology
3.4.2.2: Inflammation & Immunology
3.4.2.3: Cardiology
3.4.2.4: Neuroscience
3.4.2.5: Others
3.5: Global Biopharmaceutical CMO & CRO Market by Source
3.5.1: Mammalian
3.5.2: Non-Mammalian
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biopharmaceutical CMO & CRO Market by Region
4.2: North American Biopharmaceutical CMO & CRO Market
4.2.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.2.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.2.3: Market by Source: Mammalian and Non-Mammalian
4.2.4: The United States Biopharmaceutical CMO & CRO Market
4.2.5: The Canadian Biopharmaceutical CMO & CRO Market
4.2.6: The Mexican Biopharmaceutical CMO & CRO Market
4.3: European Biopharmaceutical CMO & CRO Market
4.3.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.3.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.3.3: Market by Source: Mammalian and Non-Mammalian
4.3.4: The Biopharmaceutical CMO & CRO Market of United Kingdom
4.3.5: The Spanish Biopharmaceutical CMO & CRO Market
4.3.6: The German Biopharmaceutical CMO & CRO Market
4.3.7: The French Biopharmaceutical CMO & CRO Market
4.4: APAC Biopharmaceutical CMO & CRO Market
4.4.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.4.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.4.3: Market by Source: Mammalian and Non-Mammalian
4.4.4: The Chinese Biopharmaceutical CMO & CRO Market
4.4.5: The Indian Biopharmaceutical CMO & CRO Market
4.4.6: The Japanese Biopharmaceutical CMO & CRO Market
4.5: ROW Biopharmaceutical CMO & CRO Market
4.5.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.5.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.5.3: Market by Source: Mammalian and Non-Mammalian
4.5.4: Brazilian Biopharmaceutical CMO & CRO Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Product
7.1.2: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Service
7.1.3: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Source
7.1.4: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Region
7.2: Emerging Trends in the Global Biopharmaceutical CMO & CRO Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biopharmaceutical CMO & CRO Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biopharmaceutical CMO & CRO Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Lonza Group Ltd.
8.2: Rentschler Biotechnologie GmbH
8.3: Boehringer Ingelheim GmbH
8.4: JRS Pharma GmbH & Co.
8.5: Inn Biologics Sdn Bhd
8.6: ProBioGen AG
8.7: Fujifilm Diosynth Biotechnologies U.S.A., Inc.
8.8: Samsung BioLogics
8.9: Toyob Co., Ltd.
8.10: Company
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biopharmaceutical CMO & CRO Market Trends and Forecast
3.3: Global Biopharmaceutical CMO & CRO Market by Product
3.3.1: Biologics
3.3.1.1: Monoclonal Antibodies (MAbs)
3.3.1.2: Recombinant Proteins
3.3.1.3: Vaccines
3.3.1.4: Antisense, RNAi, & Molecular Therapy
3.3.1.5: Others
3.3.2: Biosimilars
3.4: Global Biopharmaceutical CMO & CRO Market by Service
3.4.1: Contract Manufacturing
3.4.1.1: Process Development
3.4.1.1.1: Downstream
3.4.1.1.2: Upstream
3.4.1.2: Fill & Finish Operations
3.4.1.3: Analytical & QC Studies
3.4.1.4: Packaging
3.4.2: Contract Research
3.4.2.1: Oncology
3.4.2.2: Inflammation & Immunology
3.4.2.3: Cardiology
3.4.2.4: Neuroscience
3.4.2.5: Others
3.5: Global Biopharmaceutical CMO & CRO Market by Source
3.5.1: Mammalian
3.5.2: Non-Mammalian
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biopharmaceutical CMO & CRO Market by Region
4.2: North American Biopharmaceutical CMO & CRO Market
4.2.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.2.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.2.3: Market by Source: Mammalian and Non-Mammalian
4.2.4: The United States Biopharmaceutical CMO & CRO Market
4.2.5: The Canadian Biopharmaceutical CMO & CRO Market
4.2.6: The Mexican Biopharmaceutical CMO & CRO Market
4.3: European Biopharmaceutical CMO & CRO Market
4.3.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.3.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.3.3: Market by Source: Mammalian and Non-Mammalian
4.3.4: The Biopharmaceutical CMO & CRO Market of United Kingdom
4.3.5: The Spanish Biopharmaceutical CMO & CRO Market
4.3.6: The German Biopharmaceutical CMO & CRO Market
4.3.7: The French Biopharmaceutical CMO & CRO Market
4.4: APAC Biopharmaceutical CMO & CRO Market
4.4.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.4.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.4.3: Market by Source: Mammalian and Non-Mammalian
4.4.4: The Chinese Biopharmaceutical CMO & CRO Market
4.4.5: The Indian Biopharmaceutical CMO & CRO Market
4.4.6: The Japanese Biopharmaceutical CMO & CRO Market
4.5: ROW Biopharmaceutical CMO & CRO Market
4.5.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.5.2: Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.5.3: Market by Source: Mammalian and Non-Mammalian
4.5.4: Brazilian Biopharmaceutical CMO & CRO Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Product
7.1.2: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Service
7.1.3: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Source
7.1.4: Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Region
7.2: Emerging Trends in the Global Biopharmaceutical CMO & CRO Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biopharmaceutical CMO & CRO Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biopharmaceutical CMO & CRO Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Lonza Group Ltd.
8.2: Rentschler Biotechnologie GmbH
8.3: Boehringer Ingelheim GmbH
8.4: JRS Pharma GmbH & Co.
8.5: Inn Biologics Sdn Bhd
8.6: ProBioGen AG
8.7: Fujifilm Diosynth Biotechnologies U.S.A., Inc.
8.8: Samsung BioLogics
8.9: Toyob Co., Ltd.
8.10: Company
